SG Americas Securities
CBMG

SG Americas Securities’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

SG Americas Securities’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,165
Closed -$333K – 3548
2020
Q3 		$333K Buy
18,165
+11,435
+170% +$192K ﹤0.01% 1880
2020
Q2 		$101K Buy
+6,730
New +$96.1K ﹤0.01% 3372
2017
Q2 		– Sell
-19,270
Closed -$227K – 3653
2017
Q1 		$227K Buy
+19,270
New +$234K ﹤0.01% 2354
2015
Q3 		– Sell
-4,082
Closed -$153K – 2852
2015
Q2 		$153K Buy
+4,082
New +$132K ﹤0.01% 2118

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SG Americas Securities's CBMG Position: Q4 2020 in Review

SG Americas Securities sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 18,165 shares — an estimated $333K sold.

SG Americas Securities first reported a position in CBMG in Q2 2015 and held it in 4 quarters. The position peaked at $333K in Q3 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • SG Americas Securities reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • SG Americas Securities sold 18,165 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $333K.
  • SG Americas Securities first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 4 quarters.
  • SG Americas Securities's Cellular Biomedicine Group, Inc. position peaked at $333K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on SG Americas Securities's 13F filing for Q4 2020, filed 4 Feb 2021.